Table 3 Analysis of prescription changes due to prescription inquiries related to laboratory data.

From: Usability assessment of drug-linking laboratory data listed on prescriptions for outpatients of chiba university hospital

Classification

Baseline (11/2013–10/27/2014)

Year 1 (11/2014–10/2015)

Year 2 (11/2015–10/2016)

Year 3 (11/2016–10/2017)

Year 4 (11/2017–10/2018)

(a) Nature of prescription inquiries

     

To avoid adverse drug reactions

2

110

117

128

189

To avoid exacerbation of adverse drug reactions

0

19

24

17

24

To improve the effect of drug therapy

0

3

2

7

11

Total

2

132

143

152

224

Laboratory items

Baseline (11/2013–10/27/2014)

Year 1 (11/2014–10/2015)

Year 2 (11/2015–10/2016)

Year 3 (11/2016–10/2017)

Year 4 (11/2017–10/2018)

(b) Laboratory items that triggered prescription inquiries

     

Renal function

2

108

116

131

196

Potassium

0

11

14

13

19

Liver function

0

4

1

1

3

Neutrophil count

0

2

0

0

2

White blood cell count

0

1

2

1

1

Hemoglobin

0

1

1

1

0

Sodium

0

1

1

0

0

Cholinesterase

0

1

0

1

0

Creatine kinase

0

1

0

1

0

Hemoglobin A1c

0

1

0

0

1

PT-INR

0

1

0

2

1

Calcium

0

0

7

1

1

Blood glucose level

0

0

1

0

0

Total

2

132

143

152

224

Listing method

Baseline (11/2013–10/27/2014)

Year 1 (11/2014–10/2015)

Year 2 (11/2015–10/2016)

Year 3 (11/2016–10/2017)

Year 4 (11/2017–10/2018)

(c) Laboratory data listing method that triggered prescription inquiries

     

Standardized laboratory data

–

6

4

8

16

Drug-linking laboratory data

–

126

139

144

208

Total

–

132

143

152

224

Reason for listing

Baseline (11/2013–10/27/2014)

Year 1 (11/2014–10/2015)

Year 2 (11/2015–10/2016)

Year 3 (11/2016–10/2017)

Year 4 (11/2017–10/2018)

(d) Selection criteria for drug-linking laboratory data

     

Dose adjustment according to renal function

–

90

99

115

158

Contraindication

–

36

40

28

49

Warning

–

0

0

1

1

Total

–

126

139

144

208

Back to article page